Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 333Neoplasms 221Prostatic Neoplasms 197Carcinoma, Non-Small-Cell Lung 156Lung Neoplasms 135Pancreatic Neoplasms 118Colorectal Neoplasms 103Neoplasm Metastasis 100Carcinoma, Hepatocellular 96Leukemia, Myeloid, Acute 94Multiple Myeloma 91Brain Neoplasms 89Lymphoma 86Head and Neck Neoplasms 76Melanoma 73Ovarian Neoplasms 72Leukemia 71Leukemia, Lymphocytic, Chronic, B-Cell 69Glioblastoma 69Precursor Cell Lymphoblastic Leukemia-Lymphoma 66Colonic Neoplasms 61Recurrence 59Lymphoma, Non-Hodgkin 54Rectal Neoplasms 50Hematologic Neoplasms 50Lymphoma, Follicular 49Glioma 49Squamous Cell Carcinoma of Head and Neck 47Lymphoma, Large B-Cell, Diffuse 47Carcinoma, Renal Cell 47

Interventions

Infliximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × OTHER × Stevens-Johnson Syndrome × Clear all
NCT02126020 2017-04-07

Topical Infliximab in Autoimmune Eyes With Keratoprosthesis

Massachusetts Eye and Ear Infirmary

Phase 1/2 Withdrawn

Pemphigoid, Benign Mucous Membrane, Stevens-Johnson Syndrome, Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡